Phase 2 Randomized, Double-Blind, Placebo Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Relatecimod as Compared to Placebo in Addition to Standard of Care in Patients with Sepsis-Associatedacute Kidney Injury